1. Articles in category: PubMed

    1-24 of 776 1 2 3 4 ... 31 32 33 »
    1. The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.

      The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.

      For Immunopathol Dis Therap. 2016;7(1-2):127-139

      Authors: Ray SK

      Abstract The Krüppel-like factor 4 (KLF4) gene is located on chromosome 9q31.

      Read Full Article
    2. Effect of Lipoic Acid on the Biochemical Mechanisms of Resistance to Bortezomib in SH-SY5Y Neuroblastoma Cells.

      Effect of Lipoic Acid on the Biochemical Mechanisms of Resistance to Bortezomib in SH-SY5Y Neuroblastoma Cells.

      Mol Neurobiol. 2017 May 11;:

      Authors: Tibullo D, Giallongo C, Puglisi F, Tomassoni D, Camiolo G, Cristaldi M, Brundo MV, Anfuso CD, Lupo G, Stampone T, Li Volti G, Amenta F, Avola R, Bramanti V

      Read Full Article
    3. SAHA sensitizes neuroblastoma to paclitaxel by inhibiting TRP14-mediated autophagy.

      SAHA sensitizes neuroblastoma to paclitaxel by inhibiting TRP14-mediated autophagy.

      Cancer Sci. 2017 May 12;:

      Authors: Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y, He Y

      Abstract Paclitaxel is not as effective for neuroblastoma as most of the front-line chemotherapeutics due to drug resistance. This study explored the regulatory mechanism of paclitaxel-associated autophagy and potential solutions to paclitaxel resistance in neuroblastoma.

      Read Full Article
    4. Clinical manifestations of neuroblastoma with head and neck involvement in children.

      Clinical manifestations of neuroblastoma with head and neck involvement in children.

      Int J Pediatr Otorhinolaryngol. 2017 Jun;97:157-162

      Authors: Alvi S, Karadaghy O, Manalang M, Weatherly R

      Abstract OBJECTIVE: The purpose of our study is to review our 15-year experience with pediatric patients who have been diagnosed with neuroblastoma, and to determine their most frequent head and neck manifestations and symptoms. STUDY DESIGN: Retrospective chart review of electronic medical record.

      Read Full Article
    5. Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: A cohort study of 21,297 childhood cancer survivors.

      Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: A cohort study of 21,297 childhood cancer survivors.

      PLoS Med. 2017 May;14(5):e1002296

      Authors: de Fine Licht S, Rugbjerg K, Gudmundsdottir T, Bonnesen TG, Asdahl PH, Holmqvist AS, Madanat-Harjuoja L, Tryggvadottir L, Wesenberg F, Hasle H, Winther JF, Olsen JH, ALiCCS study group

      Read Full Article
    6. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors

      Significant antitumor effects have been observed in a variety of malignancies via blockade of immune checkpoints. Interaction of programmed death 1 (PD-1) with its ligands PD-L1 and PD-L2 suppresses T-cell function and restricts immune-mediated tumor killing. We examined expression of these proteins in children with solid tumors, as expression may serve as biomarkers of response to this class of drugs.

      Read Full Article
      Mentions: PD-1 Biomarkers
    7. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

      Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

      J Clin Oncol. 2017 May 04;:JCO2016720177

      Authors: Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D

      Read Full Article
      Mentions: MIBG
    8. Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma.

      Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma.

      Oncotarget. 2017 Apr 17;:

      Authors: He WG, Yan Y, Tang W, Cai R, Ren G

      Abstract Neuroblastoma (NB), ganglioneuroblastoma intermixed (GNBi) and ganglioneuroblastoma nodular (GNBn) are neuroblastic tumors that present with a wide range of symptoms and variable prognoses.

      Read Full Article
      Mentions: MYCN NSE
    9. High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis.

      High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis.

      Case Rep Pediatr. 2017;2017:5375091

      Authors: Yoshikawa T, Tanizawa A, Suzuki K, Ikeda K, Nomura E, Maeda Y, Tanaka N, Yamada K, Sakai Y, Imamura Y, Ohshima Y

      Abstract Renal metastasis at diagnosis with neuroblastoma is rare. We present a 14-month-old boy who was diagnosed with high-risk neuroblastoma with multiple metastases, including bilateral kidneys.

      Read Full Article
      Mentions: Metastasis
    10. Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells.

      Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells.

      PLoS One. 2017;12(5):e0176851

      Authors: Seo Y, Kim YS, Lee KE, Park TH, Kim Y

      Abstract Neuroblastoma (NB) originates from immature neuronal cells and currently has a poor clinical outcome. NB cells possess cancer stem cells (CSCs) characteristics that facilitate the initiation of a tumor, as well as its metastasis.

      Read Full Article
      Mentions: Metastasis
    11. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

      A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

      Int J Cancer. 2017 Jan 15;140(2):480-484

      Authors: Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ

      Read Full Article
      Mentions: MYCN
    12. Chemoimmunotherapeutic effect of combined treatment with ex vivo generated antigen-presenting immune cells and conventional antitumor agents in a mouse neuroblastoma model.

      Chemoimmunotherapeutic effect of combined treatment with ex vivo generated antigen-presenting immune cells and conventional antitumor agents in a mouse neuroblastoma model.

      J Pediatr Surg. 2017 Apr 21;:

      Authors: Inoue S, Setoyama Y, Odaka A, Kitagawa D, Beck Y

      Read Full Article
      Mentions: Treatment
    13. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.

      MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.

      Biochimie. 2017 Apr 26;:

      Authors: Xu Y, Chen X, Lin L, Chen H, Yu S, Li D

      Abstract PURPOSE: We evaluated the clinical relevance of microRNA-149 (miR-149) in neuroblastoma (NB) and its functional roles in regulating NB proliferation in vitro.

      Read Full Article
      Mentions: MYCN
    14. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.

      The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.

      Cancer Lett. 2017 Apr 25;:

      Authors: Lu J, Guan S, Zhao Y, Yu Y, Woodfield SE, Zhang H, Yang KL, Bieerkehazhi S, Qi L, Li X, Gu J, Xu X, Jin J, Muscal JA, Yang T, Xu GT, Yang J

      Read Full Article
      Mentions: ALK MYCN
    15. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.

      TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Apr 27;:

      Authors: Duan XF, Zhao Q

      Abstract Neuroblastomas (NB) are one of the most common extracranial solid tumors in children, and they frequently display high heterogeneity in the disease course. With ongoing research, more information regarding the genetic etiology and molecular mechanisms underlying these contrasting phenotypes is being uncovered.

      Read Full Article
      Mentions: MYCN ATRX
    16. HSD17B12 gene rs11037575 C>T polymorphism confers neuroblastoma susceptibility in a Southern Chinese population.

      HSD17B12 gene rs11037575 C>T polymorphism confers neuroblastoma susceptibility in a Southern Chinese population.

      Onco Targets Ther. 2017;10:1969-1975

      Authors: Zhang Z, Zou Y, Zhu J, Zhang R, Yang T, Wang F, Xia H, He J, Feng Z

      Abstract A previous genome-wide association study (GWAS) identified four genetic polymorphisms (rs1027702 near DUSP12, rs10055201 in IL31RA, rs2619046 in DDX4, and rs11037575 in HSD17B12 gene) that were associated with neuroblastoma susceptibility, especially for low-risk subjects. The aim of this study was to examine the association between these four polymorphisms and neuroblastoma susceptibility in a Southern Chinese population composed of 256 cases ...

      Read Full Article
    17. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.

      Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.

      Pediatr Blood Cancer. 2017 Apr 24;:

      Authors: Mody R, Zhao L, Yanik GA, Opipari V

      Abstract PURPOSE: Prognosis for relapsed/refractory high-risk neuroblastoma (HR-NBL) remains poor. Bortezomib, a proteasome inhibitor, has shown preclinical activity against NBL as a single agent and in combination with cytotoxic chemotherapy including irinotecan.

      Read Full Article
    18. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

      In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

      Drug Deliv Transl Res. 2017 Apr 21;:

      Authors: Gilabert-Oriol R, Chernov L, Anantha M, Dragowska WH, Bally MB

      Abstract Topotecan is a drug that is under investigation for the treatment of neuroblastoma and has been encapsulated into liposomes to improve its therapeutic efficacy.

      Read Full Article
      Mentions: Treatment
    19. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      Clin Cancer Res. 2017 Apr 21;:

      Authors: Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN

      Read Full Article
    20. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

      Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

      Mol Oncol. 2017 Apr 22;:

      Authors: Tucker ER, Tall JR, Danielson LS, Gowan S, Jamin Y, Robinson SP, Banerji U, Chesler L

      Read Full Article
      Mentions: ALK
    21. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Cochrane Database Syst Rev. 2017 Apr 21;4:CD010349

      Authors: Kraal KC, van Dalen EC, Tytgat GA, Van Eck-Smit BL

      Abstract BACKGROUND: Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi-modality intensive therapy.

      Read Full Article
      Mentions: MIBG
    22. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma.

      Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma.

      Cancer Med. 2017 Apr 21;:

      Authors: Maser T, Rich M, Hayes D, Zhao P, Nagulapally AB, Bond J, Saulnier Sholler G

      Abstract Catechol-O-methyltransferase (COMT) is an enzyme that inactivates dopamine and other catecholamines by O-methylation.

      Read Full Article
    1-24 of 776 1 2 3 4 ... 31 32 33 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (5 articles) MYCN
    2. (3 articles) ALK
    3. (2 articles) Metastasis
    4. (1 articles) Biomarkers
    5. (1 articles) NSE
    6. (1 articles) PHOX2B
    7. (1 articles) ATRX
    8. (1 articles) PD-1
  4. General Informations in the News

    1. (1 articles) Treatment
  5. Treatments in the News

    1. (1 articles) MIBG